Ratings Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

Equities

605016

CNE1000052N4

Food Processing

End-of-day quote Shanghai S.E. 2025-02-14 5-day change 1st Jan Change
18.51 CNY -0.22% Intraday chart for Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. +12.18% +9.53%

Highlights: Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses: Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The group usually releases earnings worse than estimated.

Ratings Chart: Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

Source: Surperformance

Add to a list
Fundamentals Valuation Revisions of Fundamental Estimates Capi.($)
- 822M
2.24B
- 1.94B
1.25B
1.02B
988M
920M
Average 1.31B
Weighted average by Cap.
See all sector ratings
Investor
Trader
ESG MSCI
-

Financials

Sales growth
EPS Growth
Profitability
Net margin
Financial Health
-

Valuation

P/E ratio
EV/REVENUE
-
EV/EBITDA
-
PBR
Yield

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions
  1. Stock Market
  2. Equities
  3. 605016 Stock
  4. Ratings Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.